Citation Tools
PDFRheumatoid arthritis
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis